United States - English - NLM (National Library of Medicine)

mirum pharmaceuticals inc. - maralixibat chloride (unii: v78m04f0xc) (maralixibat - unii:uyb6uof69l) - livmarli® is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 3 months of age and older. none. risk summary maternal use at the recommended clinical dose of livmarli is not expected to result in measurable fetal exposure because systemic absorption following oral administration is low [see clinical pharmacology (12.3)]. maralixibat may inhibit the absorption of fat-soluble vitamins [see warnings and precautions (5.3) and clinical considerations] . in animal reproduction studies, no developmental effects were observed (see data) . the estimated background risk of major birth defects for the indicated population is higher than the general population because alagille syndrome is an autosomal dominant condition. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respec

Canada - English - Health Canada

mirum pharmaceuticals, inc. - maralixibat (maralixibat chloride) - solution - 9.5mg - maralixibat (maralixibat chloride) 9.5mg

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - maralixibat chloride - solution (oral) - maralixibat chloride 10 mg/ml - maralixibat chloride - livamrli ® is an ileal bile acid transporter (ibat) inhibitor indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 1 year of age and older.

European Union - English - EMA (European Medicines Agency)

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.

United States - English - NLM (National Library of Medicine)

rxhomeo private limited d.b.a. rxhomeo, inc - asarum europaeum (unii: h0876al67a) (asarum europaeum - unii:h0876al67a) - asarum europaeum 1 [hp_x] - supressed colds condition listed above or as directed by the physician

Philippines - English - FDA (Food And Drug Administration)

zoetis philippines, inc.; distributor: zoetis philippines, inc. - inactivated avibacterium paragallinarum vaccine (vet.) - emulsion for injection (im) - formulation: each 0.5 ml (dose) contains: avibacterium paragallinarum (modesto strain) ...... 2 108.7 eid 50 avibacterium paragallinarum (spross strain) ......... 108.7 eid50 avibacterium paragallinarum (221 strain) ............. 108.7 eid50 eid - egg infective dose

Canada - English - Health Canada

laboratoires holis inc. - arum triphyllum - tablet - 3x - arum triphyllum 3x - homeopathic products

Canada - English - Health Canada

seroyal international inc. - arum triphyllum - globules - 1x - arum triphyllum 1x - homeopathic products

Canada - English - Health Canada

dolisos canada inc. - arum triphyllum - globules - 1x - arum triphyllum 1x - homeopathic products

Canada - English - Health Canada

dolisos canada inc. - asarum europaeum - globules - 1x - asarum europaeum 1x - homeopathic products